Unknown

Dataset Information

0

The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse.


ABSTRACT: Translation of therapeutic vaccines for addiction, cancer, or other chronic noncommunicable diseases has been slow because only a small subset of immunized subjects achieved effective Ab levels. We hypothesize that individual variability in the number of naive and early-activated hapten-specific B cells determines postvaccination serum Ab levels and vaccine efficacy. Using a model vaccine against the highly abused prescription opioid oxycodone, the polyclonal B cell population specific for an oxycodone-based hapten (6OXY) was analyzed by flow cytometry paired with Ag-based magnetic enrichment. A higher frequency of 6OXY-specific B cells in either spleen biopsies or blood, before and after immunization, correlated to subsequent greater oxycodone-specific serum Ab titers and their efficacy in blocking oxycodone distribution to the brain and oxycodone-induced behavior in mice. The magnitude of 6OXY-specific B cell activation and vaccine efficacy was tightly correlated to the size of the CD4(+) T cell population. The frequency of enriched 6OXY-specific B cells was consistent across various mouse tissues. These data provide novel evidence that variations in the frequency of naive or early-activated vaccine-specific B and T cells can account for individual responses to vaccines and may predict the clinical efficacy of a therapeutic vaccine.

SUBMITTER: Laudenbach M 

PROVIDER: S-EPMC4458396 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuse.

Laudenbach Megan M   Baruffaldi Federico F   Vervacke Jeffrey S JS   Distefano Mark D MD   Titcombe Philip J PJ   Mueller Daniel L DL   Tubo Noah J NJ   Griffith Thomas S TS   Pravetoni Marco M  

Journal of immunology (Baltimore, Md. : 1950) 20150513 12


Translation of therapeutic vaccines for addiction, cancer, or other chronic noncommunicable diseases has been slow because only a small subset of immunized subjects achieved effective Ab levels. We hypothesize that individual variability in the number of naive and early-activated hapten-specific B cells determines postvaccination serum Ab levels and vaccine efficacy. Using a model vaccine against the highly abused prescription opioid oxycodone, the polyclonal B cell population specific for an ox  ...[more]

Similar Datasets

| S-EPMC4018303 | biostudies-literature
| S-EPMC4644437 | biostudies-literature
| S-EPMC8063062 | biostudies-literature
| S-EPMC6676791 | biostudies-literature
| S-EPMC5975355 | biostudies-literature
| S-EPMC8547564 | biostudies-literature
| S-EPMC4407806 | biostudies-literature
| S-EPMC10218665 | biostudies-literature
| S-EPMC3637684 | biostudies-literature
| S-EPMC9314531 | biostudies-literature